ZEPP - Zepp Health Corpora... Stock Analysis | Stock Taper
Logo
Zepp Health Corporation

ZEPP

Zepp Health Corporation NYSE
$13.87 -1.00% (-0.14)

Market Cap $200.66 M
52w High $61.85
52w Low $2.22
Dividend Yield 0.84%
Frequency Special
P/E -5.42
Volume 31.80K
Outstanding Shares 14.32M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $598.12M $272.28M $-77.05M -12.88% $-77.12 $-27.19M
Q3-2025 $539.56M $212.2M $-11.5M -2.13% $-0.73 $6.44M
Q2-2025 $427.07M $198.35M $-55.64M -13.03% $-3.5 $-36.2M
Q1-2025 $279.89M $237.76M $-143.37M -51.23% $-9.32 $-130.11M
Q4-2024 $433.03M $224.49M $-268.55M -62.02% $-16.74 $-134.28M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $789.7M $3.95B $2.45B $1.5B
Q3-2025 $446.69M $4.17B $2.56B $1.61B
Q2-2025 $690.15M $3.93B $2.32B $1.61B
Q1-2025 $761.42M $3.77B $2.08B $1.69B
Q4-2024 $815.51M $3.86B $2.01B $1.84B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-11.5M $0 $0 $0 $0 $0
Q2-2025 $-55.64M $0 $0 $0 $-61M $0
Q1-2025 $-143.37M $0 $0 $0 $-50.1M $0
Q4-2024 $-269.16M $0 $0 $0 $0 $0
Q3-2024 $-92.89M $0 $0 $0 $-6.53M $0

Q4 2025 Earnings Call Summary

Read Call Summary

5-Year Trend Analysis

A comprehensive look at Zepp Health Corporation's financial evolution and strategic trajectory over the past five years.

+ Strengths

Zepp combines a sizable revenue base, solid gross margins, and a clearly defined strategic focus on health‑centric wearables and services. Its proprietary operating system, AI chips, biometric sensors, and data algorithms underpin a differentiated ecosystem, while brands like Amazfit and Zepp Clarity give it reach across multiple consumer segments. The balance sheet still shows positive equity and a meaningful cash position, providing some capacity to continue its transformation.

! Risks

Key risks center on financial sustainability and competitive intensity. The company is currently loss‑making, with negative operating and free cash flow, and relies on a cost base that is heavy relative to revenue. Leverage is meaningful and liquidity is only moderately comfortable, so prolonged cash burn would increase pressure. At the same time, Zepp faces powerful global competitors and rapid innovation cycles, which could compress margins or dilute its differentiation if execution slips.

Outlook

The outlook depends on whether Zepp can convert its innovation and ecosystem strategy into consistent profitability and cash generation before balance sheet pressures tighten. If it can scale subscription services, better leverage its technology, and bring operating costs in line with its revenue, its health‑focused platform could support a more durable business model. If not, high R&D needs, leverage, and competitive pressure may keep financial performance volatile and uncertain. Overall, the company appears to be in the middle of a strategic transition, with meaningful upside potential but also significant execution and financial risk.